

# **Sutureless Aortic Valve Replacement**

**Essay**

**Submitted for partial fulfillment of master degree in  
cardiothoracic surgery**

**By**

**Mahmoud Mohamed Gamal Ismael**

**M.B.B.CH., Resident of Cardiothoracic surgery,  
Faculty of Medicine, Minia University**

**Supervised By**

**Prof. Dr. Ahmed Hassouna**

**Professor of Cardiothoracic surgery,  
Faculty of medicine, Ain shams University**

**Prof. Dr. Hani Abd-Elmabood**

**Professor of Cardiothoracic surgery,  
Faculty of medicine, Ain shams University**

**Dr. Tamer Hikal**

**Lecturer of Cardiothoracic Surgery,  
Faculty of medicine, Ain shams University**

**2016**

# Acknowledgement

First and foremost, thanks **God** the most gracious and merciful.

I would like to express my deep thanks to **Prof. Dr. Ahmed Hassouna** , Professor of Cardiothoracic Surgery Faculty of Medicine, Ain shams university for his generous aid and supervision.

I would like also to express my deep gratitude to Professor **Prof. Dr. Hani Abd\_elmabood**, Professor of Cardiothoracic Surgery Faculty of Medicine, Ain shams university for his support.

I would also like to express my gratitude and respect towards **Dr. Tamer Hikal** Lecturer of Cardiothoracic Surgery Faculty of Medicine, Ain shams University for his continuous encouragement in completing this work.

# List of Contents

Title	Page
Introduction	1
Aim of the work	4
Review	
• Anatomy of left ventricle and aortic valve	5
• Pathophysiology of aortic valve diseases	13
• Difference between mechanical and bioprosthetic valves	26
• Preparation and selection of the patient undergoing sutureless aortic valve replacement	48
• Types and surgical procedure of sutureless aortic valve	66
• Advantages of sutureless aortic valve	82
Summary & Conclusion	93
References	95
Arabic summary	1

## List of Figures

Figure	Page No
<b>Fig.1: Dissection of LV shows its component parts and characteristically fine apical trabeculations.</b>	<b>6</b>
<b>Fig. 2: Dissection made by removing the right and part of the left aortic sinuses to show the relations of the fibrous triangle between the right and non coronary aortic leaflets.</b>	<b>7</b>
<b>Fig. 3: A schematic diagram of the relationship of the aortic valve leaflets to the structures underlying the commissures.</b>	<b>9</b>
<b>Fig. 4: The hemodynamic ventriculoarterial junction of the semilunar valves extends from the sinotubular junction across the anatomic ventriculoarterial junction to the basal ring and back in each leaflet.</b>	<b>10</b>
<b>Fig. 5: Schematic representation of a cross section through the aortic valve leaflet, showing the continuity of endocardial and endothelial components with the aortic valve.</b>	<b>10</b>
<b>Fig. 6: Positions of the aortic valve leaflets at end diastole and end systole and of a single leaflet in profile during ejection as the leaflet moves from the closed position to full opening.</b>	<b>11</b>
<b>Fig. 7: Photographs of commonly used prosthetic valves. Left: single-tilting-disk (Medtronic-Hall, Medtronic, Minneapolis, MN) valve; Right: bileaflet-tilting-disk (St Jude Medical, Little Canada, MN) valve.</b>	<b>27</b>

<b>Fig. 8: Two-way sensitivity analysis of the effects of anticoagulant-related bleeding and patient age at implantation on the recommended valve type.</b>	<b>30</b>
<b>Fig. 9: Photograph of Porcine (Carpentier–Edwards) Bioprosthesis.</b>	<b>33</b>
<b>Fig. 10: Two-way sensitivity analysis of the effects of reoperation for tissue valve failure and patient age at implantation on the recommended valve type.</b>	<b>36</b>
<b>Fig. 11: Two-way sensitivity analysis of the effects of mortality with reoperation and patient age at implantation on the recommended valve type.</b>	<b>37</b>
<b>Fig. 12: Algorithm for choice of prosthetic heart valve.</b>	<b>41</b>
<b>Fig. 13: Schematic of decision model structure. All patients are initially in the event-free state. With each 1-year cycle of the model, they can move to a different state or remain in the same state according to chance events specified under “Chance events each cycle”.</b>	<b>45</b>
<b>Fig. 14 : Factors included in logistic EuroSCORE model .</b>	<b>49</b>
<b>Fig. 15:ECG showingenlarged R wave (indicating left ventricular hypertrophy), Left ventricular strain pattern (abnormal repolarization)andDepressed ST segments and T wave inversion in leads I, aVL, V5 and V6) .</b>	<b>52</b>
<b>Fig. 16: Prominent ascending aorta with post-stenotic dilation , Calcification of the aortic valve (seen in lateral view) , Left ventricular hypertrophy (‘boot-shaped’ heart) and Left atrial enlargement in severe cases.</b>	<b>53</b>

<b>Fig. 17: Selected video frames from an echocardiogram of a child with aortic stenosis demonstrating doming (arrow) of the aortic valve (A) and turbulent flow (B) at the aortic valve (arrow) suggesting aortic valve stenosis. However, the degree of obstruction can only be assessed by Doppler-calculated peak instantaneous and mean gradients across the aortic valve (not shown). LA, left atrium; LV, left ventricle; RV, right ventricle.</b>	<b>56</b>
<b>Fig. 18: Valvular calcification of aortic stenosis seen with cardiac fluoroscopy during catheterization.</b>	<b>58</b>
<b>Fig. 19: ECG showing LVH/strain pattern of severe aortic regurgitation.</b>	<b>61</b>
<b>Fig. 20: Using Colour flow to guide CWD in aortic regurgitation.</b>	<b>63</b>
<b>Fig. 21: Aortic root angiography showing regurgitation of contrast material into the left ventricle.</b>	<b>64</b>
<b>Fig. 22: Severe aortic regurgitation. Bicuspid aortic valve (latero-lateral rim) with rupture of anterior leaflet and severe aortic regurgitation with left ventricular (LV) volume overload. Cine MRI (SSFP sequence) perpendicularly oriented through aortic valve (a), along LV outflow tract (b). Magnitude (c) and phase-contrast (d),MR image perpendicular through LV outflow tract.</b>	<b>65</b>
<b>Fig. 23: Commercially available sutureless aortic valves. (A) 3F Enable (Medtronic, Minneapolis, USA); (B) Perceval S (Sorin, Saluggia Italy); (C) Intuity (Edward Lifesciences, Irvine, USA).</b>	<b>70</b>

<b>Fig. 24: (a) Upper mini-sternotomy approach. (b) Surgical field presentation before cross clamping. (c) Surgical view of the Perceval S implantation.</b>	<b>72</b>
<b>Fig. 25: Direct echocardiographic visualization of the left ventricular outflow tract during valve insertion.</b>	<b>76</b>
<b>Fig. 26: Positioning of the transapical valve is verified using transesophageal echocardiogram with 50 % of the valve positioned above the level of the aortic annulus.</b>	<b>77</b>
<b>Fig. 27: Angiographic view of the positioning of the transapical valve prior to valve deployment. It is important to ensure that 50 % of the valve is positioned above the level of the aorta.</b>	<b>77</b>
<b>Fig. 28: The valve is deployed in position during direct fluoroscopic visualization with a brief period of rapid ventricular pacing to reduce ejection.</b>	<b>78</b>
<b>Fig. 29: Angiographic root injection is performed to confirm the position of the valve and to rule out a paravalvular or central leak.</b>	<b>78</b>
<b>Fig. 30: Short access view of the aortic valve showing the deployed Sapien valve.</b>	<b>79</b>
<b>Fig. 31: Intraoperative View of Aortic Valve Replacement via Right Anterior Thoracotomy.</b>	<b>80</b>

## List of Abbreviations

<b>2D echo</b>	Two-dimensional echocardiography
<b>ACC</b>	American college of cardiology
<b>ACT</b>	Activated clotting time
<b>AF</b>	Atrial fibrillation
<b>AHA</b>	American heart association
<b>AR</b>	Aortic regurgitation
<b>AS</b>	Aortic stenosis
<b>AVR</b>	Aortic valve replacement
<b>CABG</b>	Coronary artery bypass graft
<b>C-AVR</b>	Conventional aortic valve replacement
<b>CE</b>	Confirmatory European
<b>CPB</b>	Cardio pulmonary by pass
<b>CT</b>	Computed tomography
<b>CVA</b>	Cerebro-vascular accident
<b>CVP</b>	Central venous pressure
<b>CWD</b>	Continuous wave Doppler
<b>ECC</b>	Extracorporeal circulation
<b>ECG</b>	Electrocardiogram
<b>EF</b>	Ejection fraction
<b>HT</b>	Hypertension
<b>INR</b>	International normalized ratio
<b>IVSSG</b>	International valvular surgery study group
<b>LA</b>	Left atrium
<b>LV</b>	Left ventricle



<b>LVOT</b>	Left ventricle outflow tract
<b>MI</b>	Myocardial infarction
<b>MI-AVR</b>	Minimally invasive aortic valve replacement
<b>MRI</b>	Magnetic resonance imaging
<b>MVR</b>	Mitral valve replacement
<b>NYHA</b>	NewYork Heart Association
<b>PPM</b>	Patient prosthesis mismatch
<b>RVP</b>	Rapid ventricular pacing
<b>STS</b>	Society of thoracic surgery
<b>SU-AVR</b>	Sutureless aortic valve replacement
<b>TAVI</b>	Transcatheter aortic valve implantation
<b>TEE</b>	Trans Esophageal echocardiography
<b>TIA</b>	Transient ischemic attack
<b>TTE</b>	Trans Thoraic Echocardiography
<b>XC</b>	Cross clamp

## ***TYPES AND SURGICAL PROCEDURE OF SUTURELESS AORTIC VALVE***

Aortic stenosis is the most frequent valvular cardiac disease in the developed world, accounting for a pooled prevalence of 12.4% in the elderly population <sup>(59)</sup>.

The prognosis for symptomatic patients with severe aortic stenosis is dismal, with a one-year mortality of 30-50% <sup>(60)</sup>.

Aortic valve replacement (AVR) via median sternotomy approach, using a biological or mechanical prosthesis, has been largely shown to be safe and long-term efficacious, and thus currently represents the “gold-standard” approach for aortic stenosis treatment. <sup>(61)</sup>.

Despite excellent outcomes of conventional AVR over the past two decades, this surgical approach has evolved to become less invasive and to expand the boundaries of operability towards elderly patients presenting with multiple comorbidities and higher surgical risk. Firstly, minimally invasive aortic valve replacement (MI-AVR) has been introduced <sup>(62)</sup> and has slowly gained acceptance as a less traumatic alternative compared to median sternotomy <sup>(8)</sup>.

However, due to the technical challenges involved and the lack of data showing a substantial survival benefit and a reduced

occurrence of major post-operative complications from MI-AVR over conventional management, this approach has not been universally adopted. The observation that 30% of patients with severe aortic stenosis were not referred because they were deemed inoperable .

**Iung** <sup>(63)</sup>, has recently triggered the development of newer approaches and technologies, Compared to standard medical therapy, transcatheter aortic valve implantation (TAVI) has shown to provide a 26.8% absolute reduction in mortality at 3-year follow-up in inoperable patients <sup>(64)</sup>.

**Smith** <sup>(65)</sup> has demonstrated great potential for high-risk surgical candidates While the uptake and growth for TAVI has been enthusiastic and widespread in Europe and North America, concerns exist surrounding paravalvular leakage, vascular complications, stroke, post-operative Pacemaker implantation due to complete AV block, optimal access sites, long-term valve durability, and economic sustainability meaning that the optimal treatment of high-risk operable patients remains controversial and requires further longterm follow-up and critical assessment <sup>(66)</sup>.

The rapid technological progress of innovative surgical approaches has also resulted in the natural evolution of sutureless aortic valves from conventional sutured valves. SU-AVR, by

avoiding placement and tying of sutures after annular decalcification, has shown to minimize cross-clamp and cardiopulmonary bypass durations <sup>(8)</sup>. Shortened operational durations of SU-AVR may help reduce postoperative mortality and morbidity and improve cost effectiveness, particularly in high risk patients as well as in those undergoing complex or concomitant procedures <sup>(67)</sup>. There is a paucity of robust, evidence-based data on the role and performance of SU-AVR in minimally invasive and conventional aortic valve surgery. It is unclear how the long term outcomes of SU-AVR will compare with existing and well-accepted procedures for patients with aortic stenosis in different risk settings. A coherent and unified international collaborative effort will be necessary to provide statistically powered multi-institutional evidence to evaluate this innovative technique and direct future avenues of research <sup>(67)</sup>.

### **Sutureless aortic valves types:**

There are three main types of sutureless aortic prostheses which are currently available on the market, including the 3F Enable (Medtronic, Minneapolis, USA), Perceval S (Sorin, Saluggia, Italy) and Intuity (Edwards Lifesciences, Irvine, USA) sutureless valves (Figure 23).

The 3F Enable Sutureless aortic valve, CE mark approved in 2009, consists of a 3F stentless aortic bioprosthesis, designed to closely mimic the function of the native aortic valve. The 3F Enable is assembled from three equal sections of equine pericardial material, fixed with glutaraldehyde and mounted on a self-expanding Nitinol frame, which fixes the device in the native annulus by virtue of outward radial force. This allows for the use of one guiding stitch for correct placement of the valve to the annulus and the possibility of re-position the device if needed..

The Perceval sutureless valve was CE approved in 2011. It comprises a biological component of bovine pericardium and an elastic Ni-Ti alloy stent made of two rings and nine vertical struts, with the dual task of supporting the valve and holding it in place without any permanent suture. Its elastic properties allow the stent to adapt to the anatomy of the aorta and to follow its movements, relieving the stress on the leaflets. The valve is collapsed with an atraumatic device compression, assuring that the valve leaflets are not affected. Perceval is lowered until the correct position and then selfexpands back to its original diameter.

The design of the Edwards Intuity valve, CE approved in 2012, is based on the Perimount valve family. A balloon expandable stainless steel cloth-covered frame is incorporated

into the inflow aspect of the valve. The valve is implanted with the aid of a delivery system, which incorporates a balloon catheter used to expand the frame within the left ventricular outflow tract. The expandable frame works in conjunction with the sewing ring to position and stabilize the valve at implant. The system reduces the number of sutures required to secure the valve, while establishing the seal between the aortic annulus and the frame



**Figure 23** Commercially available sutureless aortic valves. (A) 3F Enable (Medtronic, Minneapolis, USA); (B) Perceval S (Sorin, Saluggia Italy); (C) Intuity (Edward Lifesciences, Irvine, USA).

### **Surgical Procedure of perceval sutureless valve :-**

The aortic valve was approached either by upper mini-sternotomy (Fig. 24a) or full sternotomy. CPB was performed in normothermia. After cross clamping of the aorta, myocardial protection was obtained by antegrade normothermic blood cardioplegia or crystalloid cardioplegia (Fig. 24b), according to surgeons' preferences. Transverse aortotomy is made higher than usual, 1cm distal to the sinotubular junction, leaving a free edge

for closure of the aortotomy after implantation of the device. The diseased, native aortic cusps are removed. Complete aortic annulus decalcification is not mandatory; nevertheless, bulky blocks of calcium protruding into the aortic lumen should be removed <sup>(68)</sup>.

Three guiding threads are placed at the nadir level of each resected cusp. These threads are used as reference for accurate alignment of the inflow section of the prosthesis with the insertion plane of the native leaflets. Every stitch is positioned through the aortic annulus and inside the outflow tract of the left ventricle so as to leave a margin of 2–3mm. At the prosthesis level, each thread is passed into a slot corresponding to the median part of the prosthetic sinus. The release device is inserted into the aorta to the point at which it is blocked by pulling the previously positioned thread guides. The device should form a 90 degree angle with the aortic annulus plane (Fig. 24c). The valve prosthesis, loaded into the delivery device, is released in two phases; first, the inflow section is released, followed by the release of the outflow part <sup>(68)</sup>.